Chen Y, Wang Y, Jiang X, Cai J, Chen Y, Huang H, Yang Y, Zheng L, Zhao J, Gao M. Dimethylamino group modified polydopamine nanoparticles with positive charges to scavenge cell-free DNA for rheumatoid arthritis therapy.
Bioact Mater 2022;
18:409-420. [PMID:
35415310 PMCID:
PMC8968194 DOI:
10.1016/j.bioactmat.2022.03.028]
[Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2022] [Revised: 03/15/2022] [Accepted: 03/15/2022] [Indexed: 02/06/2023] Open
Abstract
Excessive cell-free DNA (cfDNA) released by damaged or apoptotic cells can cause inflammation, impacting the progression of rheumatoid arthritis (RA). cfDNA scavengers, such as cationic nanoparticles (NPs), have been demonstrated as an efficient strategy for treating RA. However, most scavengers are limited by unfavorable biocompatibility and poor scavenging efficacy. Herein, by exploiting the favorable biocompatibility, biodegradability and bioadhesion of polydopamine (P), we modified P with dimethylamino groups to form altered charged DPs to bind negatively charged cfDNA for RA therapy. Results showed that DPs endowed with superior binding affinity of cfDNA and little cytotoxicity, which effectively inhibited lipopolysaccharide (LPS) stimulated inflammation in vitro, resulting in the relief of joint swelling, synovial hyperplasia and cartilage destruction in RA rats. Significantly, DPs with higher DS of bis dimethylamino group exhibited higher positive charge density and stronger cfDNA binding affinity, leading to excellent RA therapeutic effect among all of the treated groups, which was even close to normal rats. These finding provides a novel strategy for the treatment of cfDNA-associated diseases.
Novel dimethylamino modified PDA NPs is applied as cfDNA scavenger.
The high positively charged modified P displays high binding affinity of cfDNA.
High positive charge density of cfDNA scavenger endows high efficacy RA therapy.
Novel biocompatible cfDNA scavenger aims for cfDNA associated diseases therapy.
Collapse